Stemline Therapeutics, Inc.
↗New York, United States
Stemline Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. The company specializes in targeting cancer stem cells and developing first-in-class therapies for hematologic malignancies and solid tumors. Currently a wholly-owned subsidiary of the Menarini Group (a leading international pharmaceutical and diagnostics company with over $5 billion in annual turnover), Stemline leverages Menarini's global commercial infrastructure to expand its product portfolio internationally. The company has successfully commercialized two FDA-approved drugs: ELZONRIS (tagraxofusp), the first and only treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN), and ORSERDU (elacestrant), a selective estrogen receptor degrader (SERD) for ESR1-mutated ER+/HER2- metastatic breast cancer.
CLASSIFICATION
SIZE & FINANCIALS
Employees:501-1000
Founded:2003
Ownership:subsidiary
Status:acquired
FUNDING
Stage:Pre-IPO (was public, now private subsidiary)
Total Raised:$15.1M
Investors:Great Point Partners, Neuberger Berman, Pequot Capital Management
STOCK
Exchange:NASDAQ (historically)
Ticker:STML (delisted post-acquisition)
PIPELINE
Stage:Commercial + Clinical Development
Lead Drug Stage:FDA Approved - Commercial
Modalities:CD123-targeted cytotoxin, Selective Estrogen Receptor Degrader (SERD), Small molecule
Active Trials:6
Trial Phases:Phase 2: 3 | Phase 3: 3
FDA Approvals:2
EMA Approvals:2
CORPORATE STRUCTURE
Parent Company:Menarini Group
Acquired By:Menarini Group (2020-06-10)
Key Partnerships:Context Therapeutics: Clinical partner for ORSERDU development and commercialization, Tempus AI: AI-enabled care pathway intelligence platform collaboration for metastatic breast cancer patient identification (announced February 2025), VisualDx: Collaboration to aid in identifying patients with BPDCN (announced March 2025), Carrick Therapeutics: Clinical trial collaboration evaluating Samuraciclib and Elacestrant combination (December 2023), Insilico Medicine: Second exclusive global license agreement for AI-discovered preclinical oncology asset (January 2025), MEDSIR: Collaboration on Phase III ADELA study for advanced breast cancer
COMPETITION
Position:Leader
Competitors:NGM Biopharmaceuticals, Minerva Biotechnologies, CytomX Therapeutics, Apellis Pharmaceuticals, Intra-Cellular Therapies, Pliant Therapeutics, Pharmacyclics, Harbour BioMed +2 more
LEADERSHIP
Key Executives:
Ivan Bergstein - Chief Executive Officer and President, Founder
Ken Hoberman - Chief Operating Officer
Ron Bentsur - Director
Scientific Founders:Ivan Bergstein
Board Members:Ron Bentsur
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Stemline Therapeutics, Inc.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.